YK-2168, a potent and selective small molecule CDK9 inhibitor.

被引：0
|
作者：
Ding, Charles Z. [1 ]
Liu, Yingchun [2 ]
Zhou, Wang [3 ]
机构：
[1] WuXi AppTec, Shanghai, Peoples R China
[2] WuXi AppTec, Wuhan, Peoples R China
[3] Damei Biopharmaceut, Nanjing, Peoples R China
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5643
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Discovery and preclinical profile of YK-2168, a differentiated selective CDK9 inhibitor in clinical development
    Liu, Yingchun
    Xu, Zhaobing
    Hu, Lihong
    Xia, Li
    Li, Qi
    Zhou, Wang
    Chen, Yadong
    Li, Wei
    Jiang, Wen
    Zhu, Xingxun
    Gao, Xiao
    Xia, Yuanfeng
    Zhu, Zhenzhen
    Chen, Shuhui
    Ding, Charles Z.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2024, 112
  • [2] BLX-3030, a potent, selective, orally available small molecule CDK9 inhibitor for aggressive variant prostate cancers
    Li, Zhaoang
    Lin, Chenyu
    Medley, Kyle
    Vankayalapati, Hariprasad
    Bearss, David J.
    CANCER RESEARCH, 2024, 84 (06)
  • [3] Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers
    Freeman, David B.
    Hopkins, Tamara D.
    Mikochik, Peter J.
    Vacca, Joseph P.
    Gao, Hua
    Naylor-Olsen, Adel
    Rudra, Sonali
    Li, Huixu
    Pop, Marius S.
    Villagomez, Rosa A.
    Lee, Christina
    Li, Heng
    Zhou, Minyun
    Saffran, Douglas C.
    Rioux, Nathalie
    Hood, Tressa R.
    Day, Melinda A. L.
    Mckeown, Michael R.
    Lin, Charles Y.
    Bischofberger, Norbert
    Trotter, B. Wesley
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (23) : 15629 - 15647
  • [4] Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate
    Li, Yongtao
    Guo, Qingxiang
    Zhang, Chao
    Huang, Zhi
    Wang, Tianqi
    Wang, Xin
    Wang, Xiang
    Xu, Guangwei
    Liu, Yanhua
    Yang, Shengyong
    Fan, Yan
    Xiang, Rong
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (15) : 3231 - 3237
  • [5] Discovery of selective CDK9 small molecule inhibitors: CDK9 inhibition in tumor cells is associated with inhibition of proliferation and induction of apoptosis
    Heuer, T.
    EJC SUPPLEMENTS, 2008, 6 (12): : 94 - 94
  • [6] Discovery and characterization of selective CDK9 small molecule inhibitors in preclinical tumor models
    Heuer, Timothy
    CANCER RESEARCH, 2009, 69
  • [7] The synthesis of PROTAC molecule and new target KAT6A identification of CDK9 inhibitor i CDK9
    Mingtao Ao
    Jun Wu
    Yin Cao
    Yaohui He
    Yuxiang Zhang
    Xiang Gao
    Yuhua Xue
    Meijuan Fang
    Zhen Wu
    Chinese Chemical Letters, 2023, 34 (04) : 248 - 253
  • [8] Probing CDK1 function in human cells by a selective small-molecule inhibitor.
    Tovar, Christian
    Chen, Shaoqing
    Knezevic, Dejan
    Zhao, Xiaolan
    Sun, Hongmao
    Chen, Li
    Heimbrook, David C.
    Vassilev, Lyubomir T.
    CANCER RESEARCH, 2006, 66 (08)
  • [9] Design and characterization of highly potent and selective CDK9 heterobifunctional degraders
    Toure, Mohammed A.
    Motoyama, Keisuke
    Richters, Andre
    Koehler, Angela N.
    CANCER RESEARCH, 2023, 83 (07)
  • [10] Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
    Olson, Calla M.
    Jiang, Baishan
    Erb, Michael A.
    Liang, Yanke
    Doctor, Zainab M.
    Zhang, Zinan
    Zhang, Tinghu
    Kwiatkowski, Nicholas
    Boukhali, Myriam
    Green, Jennifer L.
    Haas, Wilhelm
    Nomanbhoy, Tyzoon
    Fischer, Eric S.
    Young, Richard A.
    Bradner, James E.
    Winter, Georg E.
    Gray, Nathanael S.
    NATURE CHEMICAL BIOLOGY, 2018, 14 (02) : 163 - +
12345